LivaNova PLC (LIVN) slipped over 11% on Thursday morning after a clinical study evaluating VNS therapy for treatment-resistant depression in unipolar patients failed to meet primary endpoints.
LIVN is currently trading at $53.11, down $6.92 or 11.52%, on the Nasdaq. The stock opened its trading at $52.35 after closing Wednesday at $60.03. The stock has traded between $42.75 and $64.47 in the past 52-week period.
LivaNova announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of VNS Therapy in treatment-resistant depression. The study did not meet its primary endpoint (PE) for the unipolar cohort; however, statistical significance was achieved in select secondary endpoints.
For comments and feedback: editorial@rttnews.com